JAK inhibitor ‘highly effective’ for alopecia areata
Trial participants taking the oral biologic had significantly improved hair regrowth and adverse events were largely mild
The rheumatoid arthritis drug baricitinib could be a highly effective therapeutic option for patients with severe alopecia areata, according to results from two phase III trials.
International researchers — including several leading Australian dermatologists — say the Janus kinase (JAK) inhibitor resulted in significantly higher rates of hair regrowth compared with placebo.
